Navigation Links
aTyr Pharma Appoints Catharine E. Johnson As Senior Vice President of Business Development
Date:6/14/2010

said Jeff Watkins, aTyr Pharma's Chief Executive Officer, adding "She brings extensive expertise in a variety of functions essential for building a strong and sustainable biotech company, and will bring substantial value to aTyr as we build our product portfolio and select strategic partners."

"Resectins are an enormous opportunity for the development of new medicines, and it is a privilege to be a part of such promising new science.  I am excited to work along side such a talented and committed management team, backed by experienced investors and successful scientific founders," said Dr. Johnson.  "Overlooked by the human genomics efforts, and with activities that are differentiated from existing therapies and common pharmaceutical discovery targets, the resectins represent a wealth of completely novel product opportunities.  The establishment of a select set of strategic partnerships will be a significant catalyst for aTyr's growth, and will enable the company to fully capture the value underlying aTyr's novel source of the resectin human proteins and drug targets."

About aTyr Pharma

aTyr Pharma engages in the generation of innovative therapeutics based on a new class of naturally occurring human proteins.  These proteins, called resectins, modulate extracellular signaling pathways in a variety of biological processes.  Resectins, previously overlooked by genomic efforts due to their hidden intra-protein location in ancient aminoacyl tRNA synthetase genes, have recently been discovered by aTyr, which is leading to connections in human physiology and pathophysiology ranging from inflammation to metabolic disease to peripheral neuropathy to blood disorders.  Resectin biology is distinct from currently known pathways and pharmaceutical targets and thus represents breakthrough opportunities for novel thera
'/>"/>

SOURCE aTyr Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Pharmatech Oncology to Present at 46th Annual DIA Meeting
2. Anthera Pharmaceuticals Promotes Colin Hislop, M.D., to Chief Medical Officer
3. INTUNIV(TM) - Shire Files Suit Against Anchen Pharmaceuticals, Inc. and Anchen, Inc.
4. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
5. Amylin Pharmaceuticals to Present at the 2010 Jefferies Global Life Sciences Conference
6. Merrimack Pharmaceuticals to Present at the Jefferies 2010 Global Life Sciences Conference
7. Merrimack Pharmaceuticals to Present at the Jefferies 2010 Global Life Sciences Conference
8. Diplomat Specialty Pharmacy Launches New Navigator Health Services to Meet Next Generation Needs of Specialty Pharmacy Industry
9. BioMed Realty Trust Breaks Ground on 176,000 Square Foot R&D Facility for Isis Pharmaceuticals in Carlsbad, California
10. Onyx Pharmaceuticals Initiates Phase 1 Study of Oral Proteasome Inhibitor in Advanced Solid Tumors
11. University of Maryland School of Pharmacy Adopts BioSoteria's eLearning Drug Safety Courses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... NY (PRWEB) August 01, 2014 ... a provider of DNA-based anti-counterfeiting technology and product authentication ... 12, 2014 to discuss its fiscal third quarter results. ... with the SEC by the end of the day ... Sciences, Inc. management will host a conference call beginning ...
(Date:8/1/2014)... AACC, a global scientific and medical professional organization dedicated ... brand identity today that reflects the organization,s commitment to ... and continue to do what they do best: provide ... they need. " The laboratory professionals ... in saving lives and making people healthier," said AACC ...
(Date:8/1/2014)... Once a decision has been made to increase ... how to define your tolerance for lowest cost design ... Director of Facilities Integration at Fluor Industrial Services, Craig ... and special guest Carrier Li, Director in Global Asset ... provide an examination of the Conceptual Design process and ...
(Date:7/31/2014)... City, CA (PRWEB) July 31, 2014 ... as consumers, are increasingly searching for food alternatives ... and nutritional benefits. The food ingredient market has ... budding players such as Vital Force Technology (VFT). ... with more than 4,000 energetic patterns, all tested ...
Breaking Biology Technology:Applied DNA Sciences to Host Conference Call Tuesday August 12, 2014 2Applied DNA Sciences to Host Conference Call Tuesday August 12, 2014 3AACC Debuts Refreshed Brand Identity 2Defining Low Cost in Your Solution for Future Facilities, New Webinar for Pharma, Biotech, Medical Device and Healthcare Companies, Hosted by Xtalks 2Functional Ingredient Manufacturer – Vital Force Technology Infuses Raw Materials & Ingredients with Subtle Energy Formula 2
... Nov. 21, 2011 WaferGen Biosystems, Inc. (OTCBB:WGBS), an ... the three and nine months ended September 30, 2011 ... adoption of its SmartChip System. "During the ... strategy to address the rapidly changing needs of the ...
... Phase I Single Dose Study Data ... Convergence Pharmaceuticals Limited ("Convergence"), the company focused ... medicines, today announces that the multiple ascending dose Phase ... channel blocker CNV2197944, for the treatment of chronic pain ...
... Japan, November 18, 2011 - A research group from ... and Fujitsu Limited today announced that research results obtained ... Bell Prize, Peak-Performance at SC11, the International Conference for ... in Seattle, on November 17 (US Pacific Standard Time). ...
Cached Biology Technology:WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy 2WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy 3WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy 4WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy 5WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy 6WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy 7WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy 8Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944 2Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944 3Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944 4'K computer' research results awarded ACM Gordon Bell Prize 2
(Date:8/1/2014)... Modern humans appear in the fossil record about 200,000 ... ago that making art and advanced tools became widespread. ... the journal Current Anthropology finds that human ... testosterone levels at around the same time that culture ... innovation, making art and rapid cultural exchange probably came ...
(Date:8/1/2014)... examining a taxonomically confused group of marine mammals ... the Australian humpback dolphin, Sousa sahulensis , ... Enterprises. , The study describing the newly ... long systematic examination of all available historical records, ... widespread group of coastal cetaceans ranging from the ...
(Date:8/1/2014)... key component of phloem, the conductive tissue through which ... molecules. Elongated cylindrical cells are capped at one end ... sieve tubes which in turn form a network throughout ... very special cells which play an important role in ... known about their differentiation," says Professor Yk Helariutta from ...
Breaking Biology News(10 mins):Society bloomed with gentler personalities and more feminine faces 2Scientists name new species of cetacean: The Australian humpback dolphin 2Scientists name new species of cetacean: The Australian humpback dolphin 3Developmental regulation of important plant phloem components discovered 2
... indicating that more than 50% of all osteoporotic hip fractures ... and treatment of osteoporotic fractures has become a major health ... Osteoporosis (IOF WCO), to be held for the first time ... the region to attend the leading global congress devoted to ...
... new drug trabectedin with pegylated liposomal doxorubicin provides clinical ... new results presented at the 33rd Congress of the ... The combination, which importantly does not include a ... women whose cancer recurs at least 6 months after ...
... N.C. A newly discovered chemical pathway that helps ... 20 common beta-blockers, drugs that are prescribed to millions ... Researchers from Duke University Medical Center tested 20 beta ... and carvedilol -- could stimulate a pathway recently found ...
Cached Biology News:IOF World Congress on Osteoporosis in Bangkok to address Asian issues 2Promising new treatment option for women with recurrent ovarian cancer 22 beta blockers found to also protect heart tissue 2
Coverslips for Microarrays, 1. *Category: MICROARRAY ACCESSORIES....
Agarase cleaves agarose to neoagaro-oligosaccharides, and is used for,quantitative, gentle recovery of DNA from low melting point agarose....
RABBIT ANTI HALOPERIDOL...
... plastic supports that retain stiffness in liquids, ... Paper segments on each strip have chemically ... indicator charts provide clear comparison. Full-range strips ... In packs of 100; each strip is ...
Biology Products: